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Background: Primary thyroid lymphoma is an uncommon pathological entity that accounts for only 1 to 5 % of all
thyroid malignancies. Primary Burkitt lymphoma of the thyroid gland is very rare. This article presents the first
Moroccan case of a primary BL of the thyroid to be reported in the literature to date.
Case presentation: We describe here a case of a 70-year-old male who developed a rapidly enlarging thyroid
gland with progressive symptoms of compression. Core biopsy confirmed the diagnosis of Burkitt lymphoma. The
patient died of septic shock, 2 weeks after the first cycle of appropriate therapeutic chemotherapy.
Conclusions: This presentation emphasizes the importance of considering lymphoma when dealing with a thyroid
mass, as its management is different from that of other thyroid pathologies, and affords an opportunity to review a
very rare type of primary thyroid lymphoma.
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Primary Burkitt lymphoma (BL) of the thyroid gland is a
very uncommon pathological entity with a few isolated
case reports in adult patients [1, 2].
This highly aggressive malignancy arises from B-
lymphoid cells. It presents usually as a rapidly expanding
thyroid mass causing compressive symptoms.
To the best of our knowledge, this article reports the
first Moroccan case of a primary BL of the thyroid to be
reported in the literature to date.
BL should be promptly recognized because its manage-
ment is quite different from the treatment of other neo-
plasms of the thyroid gland. Moreover, this disease is
quite curable if diagnosed early and treated appropriately.* Correspondence: allaoui.m1@gmail.com
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A 70-year-old male presented a rapidly expanding mass
of the neck associated with history of airway compres-
sion symptoms; progressive dyspnea and dysphonia last-
ing for 4 weeks, in a context of apyrexia and impairment
of general condition. The patient was admitted to the
hospital because of increasing dyspnea and urgently re-
ceived a tracheostomy.
A biopsy of the cervical mass was carried out and the
histological examination showed diffuse infiltration of the
thyroid gland by a monotonous population of atypical
intermediate-sized lymphoid cells (Fig. 1). These last pos-
sess scanty amphophilic to basophilic cytoplasm with cen-
trally located nuclei of irregular shape, displaying dispersed
basophilic chromatin, and frequent apoptotic figures (Fig. 2).
Scattered tingible body type macrophages were also
present. Little residual thyroid follicles and some areas of
necrosis was observed.
Immunohistochemical staining was then performed
and the tumour cells were positive for CD20, CD10 andis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Low magnification showing a diffuse infiltration of atypical
lymphoid cells in the thyroid gland (haematoxylin & eosin stain, ×50)
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100 %. CD3 and CD5 stained the background T cells
(Fig. 3). Immunoreactivity for Epstein-Barr virus (EBV)
was negative. The diagnosis of BL was confirmed on
fluorescence in situ hybridisation that showed tumour
cell positivity for the t (8; 14) translocation. Bone mar-
row examination was normal.
The patient was transferred to the Clinical Haematology
department. On physical examination, he was apyretic
and hemodynamically stable with a cervical armouring by
a huge mass of hard consistency. Neurological examin-
ation shows no sensorimotor deficits.
Other systemic examinations were normal, without
any palpable lymphadenopathy or organomegaly.
The computerized tomography (CT) scan showed a
heterogeneous process of the thyroid gland measuring
10.5 × 8.2 × 6.5 cm in size, extending up towards theFig. 2 Higher magnification showing a monotonous population of
intermediate-sized lymphoid cells with scant dark blue cytoplasm,
small cytoplasmic vacuoles and tingible-body macrophages
(haematoxylin & eosin stain, ×400)laryngeal region, infiltrating the right vocal cord and re-
ducing the laryngeal lumen (Fig. 4).
The thoraco-abdominal CT scan showed no other
localization.
The examination of the cephalorachidian liquid showed
no central nervous system involvement. The patient was
diagnosed with thyroidal Burkitt lymphoma, stage I of
Murphy [3].
After cardiac, renal and liver functions assessment, the
patient received chemotherapy according to the
LMBA02 protocol [4], group A (Age > 60 years, no CNS
nor bone marrow involvement), with a first course of
COP (Cyclophosphamide, Vincristine and Prednisone)
and intrathecal Methotrexate, followed a week after by a
course of R-COPADEM (Rituximab at day 0 and day 6,
Cyclophosphamide day 2,3 and 4, Prednisone from day 1
to 5, Doxorubicineat day 2, high dose Methotrexate at
day 1 with folic acid rescue from day 2 to day 6 and
intrathecal chemotherapy at day 2 and day 6).
At day 15 of chemotherapy, the patient developed fe-
brile neutropenia, refractory to broad-spectrum antibi-
otics and antifungals. The evolution was marked by the
installation of a septic shock with acute respiratory dis-
tress syndrome that led to his transfer to intensive care
unit where he was intubated and ventilated. The patient
died 2 days after.
Discussion
Primary thyroid lymphoma (PTL) is defined as a lymph-
oma involving only the thyroid gland or the thyroid
gland and adjacent (regional) neck lymph nodes, without
contiguous spread or distant metastases from other
areas of involvement at diagnosis [5].
PTL is an uncommon pathological entity that accounts
for only 1 to 5 % of all thyroid malignancies, comprises
approximately 2 % of all malignant extra nodal lymph-
omas and which predominantly originate from B lym-
phocytes [5, 6].
The common histological subtypes are diffuse large B-
cell lymphoma and mucosa-associated lymphoid tissue
(MALT) lymphoma [6–9]. Primary Burkitt lymphoma of
the thyroid is very rare with a few isolated case reports
(Table 1) [1–3, 10, 11].
Burkitt lymphoma is a highly aggressive disease that is
endemic in Africa and sporadic in other parts of the
world. The endemic variant is associated with Epstein-
Barr virus.
BL was one of the first tumours shown to have a
chromosomal translocation that activates an oncogene
(c-MYC) [12, 13].
Normally, the thyroid gland does not contain native
lymphoid tissue, therefore, the intrathyroid lymphoid tis-
sue that causes thyroid lymphoma comes from the mi-
gration of lymphoid tissue into the thyroid during an
Fig. 3 Immunohistochemical staining revealed the expression of CD20 (a) and CD10 (b) by the neoplastic cells. Keratin highlights the
lymphoepithelial lesions (c). Ki-67 immunostaining showed a high proliferation index (d)
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mon condition resulting in lymphoid migration is
autoimmune thyroiditis (i.e., Hashimoto’s thyroiditis)
[14–16]. Large adult population-based as well as
retrospective clinicopathological case series suggest
that primary thyroid Non-Hodgkin lymphoma NHL
typically occur in middle to older-aged persons and
have a predilection for females (it have also shown
that patients with chronic lymphocytic thyroiditis
have a greater risk of subsequently developing thyroidFig. 4 CT showing a large heterogeneous mass of the thyroid glandlymphoma when compared to age and gender
matched normal individuals) [5, 6, 16–21].
Clinically, lymphomas originating in the thyroid can fre-
quently mimic anaplastic thyroid carcinoma in that both
have similar clinical characteristics of rapid growth, which
might be associated with compression symptoms dyspnea,
dysphagia, pain and hoarseness of voice [2, 22–25].
Ultrasonography is generally the initial diagnostic modal-
ity used in the workup of thyroid enlargement and nodules.
Although nonspecific, there are certain characteristics that
Table 1 Clinical and pathological characteristics of patients with primary Burkitt lymphoma of the thyroid gland in the literature
Author Age
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internal echoes, borders, and posterior echoes. For
example, Enhanced posterior echoes help in distinguishing
lymphoma from other types of thyroid lesions [26, 27].
Once PTL is suspected based upon clinical presenta-
tion and ultrasound findings, the next step in diagnosis
is biopsy. Traditionally, open surgical biopsy was felt tobe necessary to differentiate thyroid lymphoma from
thyroiditis and anaplastic carcinoma. However, with re-
cent advances in immunophenotypic analysis, the accur-
acy of fine-needle aspiration (FNA) has improved. These
advances in diagnosis of PTL mirror those seen with sys-
temic lymphomas with a reported accuracy rate of FNA
of 80–100 %. Nevertheless, there are still challenges in
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the histological similarities with thyroiditis and the high
coincidence of these pathologies within the same gland,
which results in increased false-negative rates from sam-
pling error [26].
Histologically, the tumour cells of BL are medium-sized
cells (nuclei similar or smaller to those of histiocytes) and
show a diffuse monotonous pattern of growth. The cells
appear to be cohesive but sometimes exhibit squared-off
borders of retracted cytoplasm. The nuclei are round with
finely clumped and dispersed chromatin, with multiple
basophilic medium-sized, paracentrally situated nucleoli.
The cytoplasm is deeply basophilic and usually contains
lipid vacuoles. The tumour has an extremely high prolifer-
ation fraction (many mitotic figures) as well as a high frac-
tion of apoptosis. A “starry sky” pattern is usually present,
which is imparted by numerous benign macrophages that
have ingested apoptotic tumour cells [28].
In Burkitt lymphoma, the tumour cells express moder-
ate to strong levels of membrane IgM with light chain
restriction and B-cell-associated antigens (CD19, CD20
and CD22), CD10, BCL6, c-MYC and CD38. The neo-
plastic cells are usually negative or only weakly positive
for BCL2 and are uniformly TdT and MUM-1/IRF-4
negative. Nearly 100 % of the cells are positive for Ki67.
There are very few admixed T-cells [12, 28–30]. In the
present case, the immunophenotype of the atypical
lymphoid cells was consistent with these features.
Burkitt lymphoma is characterized at the molecular
level by a reciprocal translocation involving the c-MYC
proto-oncogene, which normally resides on chromosome
8q24. The most common translocation in Burkitt lymph-
oma is a t (8;14) (q24;q32), which results in the trans-
location of c-MYC to the B-cell heavy-chain gene locus
on chromosome 14q32. This translocation occurs in ap-
proximately 80 % of Burkitt lymphoma cases regardless
of the clinical setting. Other variant translocations in-
volve the translocation of c-MYC to the kappa light
chain locus on chromosome 2, t (2;8) (p12;q24), which
occurs in approximately 15 % of cases, and translocation
of c-MYC to the lambda light-chain locus on chromo-
some 22, t (8;22) (q24;q11), which occurs in approxi-
mately 5 % of cases [12, 28, 31].
In addition, it has been confirmed that the occurrence
of BL is associated with viral infections, particularly EBV
infection. However, the EBV detection rates in different
subtypes of BL also vary [32]. EBV infection is detected
in the vast majority of endemic BL and ~30 % of spor-
adic BL [12, 30, 32].
Treatment of Burkitt lymphoma in most centers is
guided by the FAB LMB study (cooperative study be-
tween the Children’s Cancer Group, the Societé Fran-
caise d’Oncologie Pediatrique, and the UK Children’s
Cancer Study Group) [33, 34]. The former consists ofinitial cytoreduction with cyclophosphamide, prednisol-
one, and vincristine, followed by more intensive chemo-
therapy in varying combinations containing doxorubicin,
alkylators, vincristine, etoposide and therapy directed to
eradicate or to prevent CNS disease such as high dose
methotrexate [3, 12].
Aggressive high-dose therapy is needed for adult Burkitt
lymphoma. However, interpretation of response is difficult
because most studies of this approach have been done
with a single protocol in mainly young adults. The regi-
men generally used in the UK and USA is cyclophospha-
mide, vincristine, doxorubicin, and highdose methotrexate
alternating with ifosfamide, etoposide, and high-dose
cytarabine [12].
The use of a less toxic dose adjusted EPOCH (etopo-
side, prednisone, vincristine, cyclophosphamide, adria-
mycin) plus rituximab (DA-REPOCH) led to an event
free survival of 96 % and an overall survival of 100 %
with a median follow up to 86 months in a small studay
that included 19 HIV negative patients [35]. The use of
rituximab (anti-CD20) in primary therapy has been
assessed and a randomized clinical trial including 257
patients demonstrated that the addition of rituximab to
the LMB regimen improved the event free survival and
the overall survival without adding more toxicities [4].Conclusions
In summary, the current study presents a case of spor-
adic primary BL of the thyroid occurring in a seventy-
year-old male, which exhibited the typical morphological
features and immunophenotype of BL and which, to the
authors’ knowledge, is the first case of BL of the thyroid
gland to be reported in Morocco. We also emphasize
here the importance of considering lymphoma when
dealing with a thyroid mass, as its management is differ-
ent from that of other thyroid pathologies and delaying
treatment has an impact on prognosis.Consent
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